Results 81 to 90 of about 40,707 (134)

Adjuvant treatment for acral melanoma. [PDF]

J Eur Acad Dermatol Venereol
Komori T, Nakamura Y.
europepmc   +1 more source

Efficacy and CNS Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multicenter Basket Trial Analysis (NCI/SWOG S1609). [PDF]

Clin Cancer Res
Ahluwalia MS, Solomon S, Patel SP, Sarfraz Z, Othus M, Chae YK, Kurzrock R.   +6 more
europepmc   +1 more source

Aseptic meningitis induced by monoclonal antibodies used in cancer treatment: a systematic review. [PDF]

Res Pharm Sci
Ghalandari N, Ataei S, Esfahani FN, Emami S.   +3 more
europepmc   +1 more source

Perioperative immunotherapy for advanced resectable melanoma: a cost-effectiveness analysis. [PDF]

BMC Health Serv Res
Rui M, Wei Q, Wang Y, You JHS.
europepmc   +1 more source

Nivolumab rechallenge after pituitary apoplexy associated with nivolumab plus ipilimumab in a patient with pituitary adenoma and rectal melanoma: a case report and literature review. [PDF]

J Pharm Health Care Sci
Imai C, Uchida M, Takahashi K, Ohno I, Takiguchi Y, Ishii I.   +5 more
europepmc   +1 more source

Compartment-specific immune and tumor markers associated with clinical outcomes in patients with and without sarcomatoid/rhabdoid renal cell carcinoma treated with ipilimumab and nivolumab. [PDF]

ESMO Open
Savion-Gaiger N, Perales O, Su DG, Bar-Ziv D, Challa P, Djureinovic D, Yi I, Adeniran A, Kluger H, Schoenfeld D.   +9 more
europepmc   +1 more source

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. [PDF]

Cancer
Luo J, Li Z, Ge J, Cai S, Mo X, Liu W, Gui C, Du Q, Liu J.   +8 more
europepmc   +1 more source

Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. [PDF]

J Clin Oncol
Scherpereel A, Baas P, Nowak AK, Tsao AS, Fujimoto N, Peters S, Mansfield AS, Popat S, Bautista Aragon Y, Talbot T, Grossi F, Kowalski D, Kaplan MA, Cardona AF, Soomro R, Hu N, Lee A, Ip V, Hung YH, Zalcman G.   +19 more
europepmc   +1 more source

Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315). [PDF]

Oncologist
Mandl A, Chen R, Das S, Strosberg JR, Kasi A, Konda B, Li D, Burns TF, Chauhan A, Ciombor KK, Dayyani F, Dorff T, Ohr JP, Patel BB, Sukrithan V, Soares HP, Chen K, Liu SV, Tesfaye AA, Carducci MA, Beumer JH.   +20 more
europepmc   +1 more source